Call Us Today:

Atypical Melanocytic Lesions

Home > Diagnosis > Melanoma > Atypical Melanocytic Lesions

Treatment for Atypical Melanocytic Lesions


Atypical melanocytic lesions are also known as atypical melanocytic hyperplasia, atypical mole, or dysplastic mole. The majority of these are benign, however, some have a significant risk of developing into melanoma or actually being a melanoma. This terminology is applied based on either a visual inspection or a biopsy of the lesion.


Visual examination of skin can often identify suspicious lesions requiring further evaluation. Five visual characteristics are used to identify the risk of invasive melanoma:


A - asymmetry of lesion shape

B - borders that are irregular or blurred

C - color that is variable within a single lesion or different from other moles

D - diameter greater than 6 mm

E - evolution of a mole's appearance - size, color, or shape


These are indicators for  a biopsy to rule out melanoma.


Atypical melanocytic lesions are pigmented moles that have been found to have abnormal cells and are assumed to be at risk for developing into a malignant melanoma. These lesions, once diagnosed as atypical, are typically excised to eliminate the risk of cancer. Although this seems like a prudent approach, scientific evidence for this is frequently lacking. Rationale for excision is based on clinical standards for treating melanoma-in-situ or lentigo maligna.


There are three levels of classification of atypical melanocytic lesions:

  • mild atypia in a melanocytic lesion
  • moderate atypia in a melanocytic lesion
  • severe atypia in a melanocytic lesion


Most pathologists regard mild and moderate atypia synonymously.


Only melanoma-in-situ has adequate evidence to support surgical excision. This particular lesion carries a 5-10% risk of degenerating into malignant melanoma over a 50 year lifetime. This breaks down to a risk of 1-2% per decade. What no one knows is the risk of the atypical melanocytic lesions. Logic would dictate that the risk would be even lower - if present at all.


The complete diagnosis of a melanocytic lesion requires a complete excision. These lesions frequently exhibit heterogeneity - variability of abnormality. In other words a lesion with moderate atypia may contain areas of melanoma-in-situ within it. Melanoma-in-situ lesion may contain areas of invasive malignant melanoma. Frequently, this variability is visible with a naked eye and guides clinical decision making.


The controversy arises when a biopsy is read as atypical melanocytic lesion with involved margins, and the pathologist recommends additional margin excision. From pathologist's perspective only a complete lesion removal allows for a definitive diagnosis. Complete excision of these atypical melanocytic lesions requires 2 mm margins around the visible lesion for complete clearance. Although most surgeons will not hesitate to excise these lesions completely, scientific evidence to support such approach is lacking. There little evidence that incomplete excision and subsequent lesion recurrence exposes the patient to a greater invasive melanoma risk.  Furthermore, cosmetic considerations may be significant in sensitive areas such as the nose or eyelids. Additional 2 mm margins on all sides of the lesion can drastically change the reconstruction and the outcome. So, each patient and each lesion musts be treated with individual considerations and not necessarily rigid protocols.


For in depth discussion of the risks of atypical nevi read this article.


Related Articles

Severe Lichenoid Drug Eruption from Pembrolizumab
HISTORY An 88-year-old woman with a six-month history of a diffuse, pruritic eruption that includes thick, hypertrophic leg lesions with accompanying edema, ulcerations, weeping exudates and pain. The eruption started during a course of pembrolizumab (keytruda) infusions for high risk melanoma of the left great toe. Last Keytruda infusion was three months ago. DISCUSSION  Pembrolizumab,…
Read More
Desmoplastic / Spindle Cell Melanoma of the Scalp
A 67-year-old man with CLL presents with 3 month h/o 3 cm dense dermal growing scalp mass. Incisional biopsy showed spindle cell melanoma. The tumor was resected with a 2 cm margin. Final pathology showed malignant melanoma—spindle cell / desmoplastic type. Additional 1.2 cm margin was resected for wide clearance creating a 10 x 9…
Read More
Evaluation of Longitudinal Melanonychia
HISTORY An 84-year-old woman with a history of melanoma of the left upper back presents with an 11 month h/o left great toe discoloration. Biopsy of left great toe was performed on 08/05/2019. Previous h/o discoloration of the right fifth toe was biopsied and was negative for malignancy. DISCUSSION What is the cause of melanonychia…
Read More
Near-Infrared Laser Lymphangiography Sentinel Lymph Node Biopsy for Melanoma
HISTORY A 61-year-old male presents for 1.5 cm malignant melanoma of left posterior shoulder invading to at least 1.2 mm (Clark’s Level IV) on a shave biopsy. Left shoulder melanoma was excised, and a left axillary sentinel lymph node was biopsied. Small focus of residual melanoma was found in the primary site, but none in…
Read More
Management of Recurrent Large Melanoma In Situ
HISTORY 78-year-old man presents with a recurrent melanoma in situ of left cheek in April 2018. Previously, the melanoma in situ was excised in 2001. Patient’s dermatologists performed excision in three stages over a period of 3 weeks to achieve clear margins.  Reconstruction of left cheek was performed with a cheek and neck platysma myocutaneous…
Read More
Melanoma within recurrent MIS
HISTORY   73-year-old woman presents with 1-year history of recurrent pigmented lesion of the right nasal ala  found to be invasive melanoma with 0.5 mm invasion. Patient’s history began 9 years ago in 2009 with excision of a melanoma in situ and skin graft closure. In 2012, pigmentation adjacent to the graft site was found…
Read More


Receive research updates, inspiring stories, healthy living tips and more.

Something went wrong. Please check your entries and try again.



© 2018 SCARS Management Services. All rights reserved.